US OptionsDetailed Quotes
SLRN250117C12500
- 0.00
- 0.000.00%
15min DelayClose Jan 17 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover0.00%IV528.14%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.54Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Acelyrin Stock Discussion
ACELYRIN Inc - Lonigutamab Shows Potential Efficacy and Favorable Safety Profile in Ted
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
Thursday, 2nd January at 8:00 pm
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to pro...
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
ACELYRIN (Nasdaq: SLRN) announced that its Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis failed to meet its primary endpoint of showing statistically significant improvement in time to treatment failure versus placebo at 24 weeks. Secondary endpoints also did not achieve statistical significance.
Following these results and previous guidance, AC...
No comment yet